Robotic Segmentectomy: We Are Still on the Way

Yajie Zhang,Jiahao Zhang,Hecheng Li

DOI: https://doi.org/10.1016/j.jtcvs.2020.04.072

2020-01-01

Abstract:We appreciate the response to our commentary by Liu and colleagues 1 regarding the study by Razi and colleagues 2 evaluating segmentectomy versus lobectomy for cT1 N0 M0 nonsmall cell lung cancer who were discovered to have "unsuspected" pathologic N1 or N2 disease.We largely agree with the key points raised by Liu and colleagues.Appropriate selection of patients for segmentectomy is critical.In general, segmentectomy can be a reasonable choice for small, peripheral tumors that are 2 cm in diameter when a segmental margin that is greater than or equal to the tumor diameter is achievable, particularly in patients with advanced age, who are frailer and have reduced cardiopulmonary reserve.There are 2 ongoing randomized controlled trials-the results of which are eagerly anticipated-designed to further improve our understanding of patient selection for limited resection for cT1a (peripheral tumors <2 cm) N0 M0 non-small cell lung cancer: CALGB 140503 3 and JCOG0802/WJOG4607L. 4 In the era of lung cancer screening and increased identification of small, peripheral tumors, the uncommon scenario of unsuspected N1 and N2 disease during a segmentectomy will likely become more frequent.It will be important to continue evaluating questions regarding the extent of parenchymal resection in the setting of N1 and unsuspected N2 disease in well-designed multicenter studies that have granular data that include details about N1 and N2 lymph nodes and that have data regarding pulmonary function.